OMERACT 2016 — International Consensus Conference on Outcome Measures in Rheumatology, Whistler, British Columbia, Canada, May 2016

Introduction P. Tugwell, S. Grosskleg, B. Shea, D. Beaton, G.A. Wells ........................................1511

Workshops and Special Sessions

The OMERACT Core Domain Set for Outcome Measures for Clinical Trials in Polymyalgia Rheumatica S.L. Mackie, H. Twohig, L.M. Neill, et al, on behalf of the OMERACT PMR Working Group ..........................1515

Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016 A.M. Orbai, M. de Wit, P.J. Mease, et al .................................1522

OMERACT Endorsement of Patient-reported Outcome Instruments in Antineutrophil Cytoplasmic Antibody–associated Vasculitis J.C. Robson, G. Tomasson, N. Milman, et al .....................1529


Toward the Development of a Core Set of Outcome Domains to Assess Shared Decision-making Interventions in Rheumatology: Results from an OMERACT Delphi Survey and Consensus Meeting K. Toupin-April, J. Barton, L. Fraenkel, et al .........................1544


The OMERACT First-time Participant Program: Fresh Eye from the New Guys V.S. Sloan, S. Grosskleg, C. Pohl, G.A. Wells, J.A. Singh .................................1560

Correspondence

What is the Definition of the Anticytoplasmic Autoantibody? Y. Chen, J. Liu ........................................1564

Anti-tRNA Synthetase-specific Immunofluorescence Patterns are Easily Detected in the Suitable Substrate L.H. Jeam, T.Y. Kim .................................1564

Reply R. Aggarwal, C.V. Oddis .................................1565

Large-vessel Involvement and Varicella Zoster Virus Vasculopathy in Giant Cell Arteritis–related Stroke: Something to Keep an Eye On G. Vitiello, D. Cammelli .................................1566

Reply H. de Boysson, A. Aouba ................................1567

Correction


Meetings in Rheumatology ........................................x